TOMI Environmental Solutions announced a significant expansion across Canada, securing placements in the country’s largest health research organization, leading hospital systems, a Nova Scotia trauma center, and a research university. The company integrated its SteraMist iHP decontamination technology into the special pathogens unit of the research organization, marking a key milestone in its North American growth strategy.
The Canadian expansion is part of a series of strategic wins that began in late 2025 and continued into early 2026. In addition to the new placements, TOMI has partnered with Betatek, which became the company’s official distributor in Canada in December 2024, and with Total Clean Air, which was named the preferred European partner in March 2026. The company also secured a $500,000 contract with a biopharmaceutical firm to deploy SteraMist Integrated Systems.
"Our continued expansion in Canada reflects a shift toward more advanced, automated decontamination solutions across regulated healthcare and research environments," said Elissa J. Shane, Chief Operating Officer. "By securing placements in both elite research laboratories and critical care hospitals, we are reinforcing SteraMist iHP decontamination technology as the gold standard for pathogen control while supporting our expansion in North America."
While the new Canadian placements represent a significant revenue opportunity, TOMI’s financial profile remains challenging. The company has reported negative revenue growth of 4.3% over the past three years, net and operating margins of –91.4% and –94.16% respectively, and a debt‑to‑equity ratio of 1.56. The company has also issued convertible notes to raise additional capital.
The expansion positions TOMI to capture a larger share of the North American decontamination market by securing recurring service and consumable sales in high‑containment environments. The company’s razor‑blade model—selling equipment and then generating ongoing revenue from consumables—underpins this strategy, and the Canadian placements are expected to strengthen the recurring revenue stream.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.